XOMA Royalty Corp: 2025 Review and 2026 Investor Outlook

Key Highlights from XOMA Royalty Corp’s Corporate Update

• Strategic Business Model: XOMA positions itself as a “Biotech Royalty Aggregator,” focusing on acquiring milestone and royalty interests in a diverse portfolio of drug candidates and marketed products.
• 2025 Portfolio Expansion: XOMA added multiple royalty and milestone assets through creative deal-making, including acquisitions and licensing agreements across several biotech companies.
• Significant Share Buyback: The company returned substantial capital to shareholders in 2025, repurchasing 648,048 shares at a cash cost of \$16 million.
• Robust Cash Position: XOMA ended 2025 with approximately \$133 million in cash, cash equivalents, and restricted cash, with \$82 million unrestricted, supporting future deals and financial flexibility.
• Litigation Against Janssen Biotech: XOMA initiated legal action against Janssen Biotech, Inc., claiming breach of contract and unjust enrichment over Janssen’s alleged unauthorized use of XOMA’s intellectual property in the commercialization of TREMFYA (guselkumab). This litigation could have material financial implications.
• Financial Performance: In FY2025, XOMA received approximately \$49–50 million in cash from royalties and milestones. The company’s general and administrative expenses included an increase of about \$1 million related to ongoing litigation efforts.
• Growing Asset Portfolio: XOMA has built a diversified portfolio with over 100 assets, including commercial-stage products and drugs in development, providing stable and growing royalty streams.
• Upcoming 2026 Catalysts: Multiple regulatory, commercial, and clinical milestones are anticipated in 2026, including Phase 2b and Phase 3 data readouts and potential product launches that could impact future royalty income.

2025 Review: Portfolio Growth and Shareholder Returns

Throughout 2025, XOMA Royalty Corp significantly expanded its royalty and milestone portfolio by executing numerous acquisitions and licensing deals. Notable additions include royalties related to mezagitamab (Phase 2 & 3), as well as assets from companies such as KNT, Mirum, and Takeda. These deals were largely non-dilutive, and some benefitted from favorable tax treatment (Section 174 deductions), further enhancing shareholder value.

The company also monetized certain pipeline assets, streamlining its portfolio and returning excess capital to shareholders via a substantial share buyback program. In total, 648,048 shares were repurchased at a cost of \$16 million, underscoring management’s confidence in the company’s valuation and future prospects.

Financial Strength and Capitalization

As of December 31, 2025, XOMA reported a strong cash position of approximately \$133 million, including \$82 million in unrestricted cash. The company’s market capitalization (fully diluted) stood at roughly \$549 million, with an enterprise value of \$449 million and a royalty-backed loan of \$113 million. This robust financial profile provides XOMA with the resources needed to pursue additional royalty acquisitions and weather market uncertainties.

Litigation with Janssen Biotech: Potential Share Price Impact

A key development for shareholders is XOMA’s ongoing litigation against Janssen Biotech, Inc. The lawsuit alleges breach of contract and unjust enrichment stemming from Janssen’s alleged unauthorized use of XOMA’s intellectual property in the commercialization of TREMFYA. Legal expenses in 2025 increased by approximately \$1 million due to this case. The outcome is uncertain, but a favorable resolution could yield significant financial recovery for XOMA, potentially moving the share price. Conversely, adverse outcomes or prolonged litigation could increase costs and weigh on investor sentiment.

Pipeline and Revenue Streams: Stability and Growth

XOMA’s portfolio now includes over 100 assets, with several commercial-stage products generating stable and growing royalty streams. Key marketed products span therapeutic areas such as wet age-related macular degeneration, diabetic macular edema, relapsed/refractory pediatric low-grade glioma, Niemann-Pick Disease Type C, and hemophilia B, among others. Estimated royalty receipts for 2025 totaled \$22.5 million from a wet AMD product, with peak sales projections of \$5.8–8.3 billion for the underlying drugs, highlighting the scale of potential future income.

The company is also positioned to benefit from upcoming clinical and regulatory milestones in 2026, including Phase 2b and Phase 3 data announcements for assets such as seralutinib, volixibat, rilvegostomig, and others. These catalysts could drive additional growth in royalty receipts and support further share price appreciation.

Shareholder Considerations and Outlook

• Litigation Risk: The outcome of the Janssen Biotech litigation is a key risk and opportunity for shareholders, with the potential for both material upside and downside.
• Deal Pipeline: XOMA’s capacity to deploy capital into new royalty deals remains strong, and further acquisitions or partnerships could be catalysts for future growth.
• Return of Capital: The recent share buyback program demonstrates management’s commitment to shareholder returns and could continue if surplus capital remains available.
• Upcoming Milestones: Several regulatory and clinical catalysts in 2026 could impact the company’s cash flow and share price.

Conclusion

XOMA Royalty Corp enters 2026 with a strengthened balance sheet, a larger and more diversified royalty portfolio, and several potential value catalysts on the horizon. The ongoing Janssen litigation is a key event to monitor, as its outcome could significantly impact shareholder value. Investors should also watch for upcoming clinical and regulatory milestones that may drive further growth in royalty income and support share price appreciation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisor before making investment decisions. Past performance is not indicative of future results. The outcome of pending litigation and the realization of future royalty streams are subject to significant uncertainty and risk.

View XOMA Royalty Corp Historical chart here